Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 14th Preview)
-
FDA multiple myeloma approval for new CELMoD class
The FDA granted accelerated approval to Bristol Myers Squibb’s iberdomide (Zenbexus), an oral CELMoD regimen for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy. The clearance marks the debut of this novel drug class in myeloma in the U.S. and is tied to a more sensitive remission endpoint than regulators have traditionally used in the disease space. The approval is based on Phase 3 data showing Zenbexus plus daratumumab (Darzalex) and dexamethasone improved the rate of minimal residual disease (MRD)-negative status versus a bortezomib (Velcade)-based comparator. BMS reported 41% of recipients achieving MRD-negative status versus 21% on Velcade. Full survival data are still pending. BMS positioned Zenbexus for second-line use alongside Darzalex and dexamethasone, with investors and analysts expecting the regimen to reshape treatment sequencing and combination selection. The company also has a “maintenance” study underway in patients post–bone marrow transplant, which could broaden uptake if it demonstrates durable control. Separately, BMS is expected to report additional data in coming months that may support conversion from accelerated to full approval.
-
Duchenne therapy: Capricor seeks FDA review after advisory setback
Capricor Therapeutics said it will ask the FDA to review additional data after a negative vote from an advisory committee regarding its Duchenne muscular dystrophy cell therapy. The company framed the next step as an attempt to improve its likelihood of approval in a narrower intended indication. Capricor indicated it will file supplemental analyses and updated materials, aiming to address the committee’s questions and the basis for the negative recommendation. The move follows a sharp market reaction to CEO comments that the FDA was “willing to review” an amended submission. The development keeps Capricor’s program alive for a potential regulatory path even as it highlights how sensitive DMD manufacturing and clinical endpoint questions can be for regulators. Observers will be watching how Capricor characterizes efficacy, safety, and patient selection in the renewed materials.
-
Gene therapy dealmaking: PTC wins Sangamo Fabry program in bankruptcy auction
PTC Therapeutics won a competitive bankruptcy auction for Sangamo Therapeutics’ Fabry disease gene therapy program, securing the ST-920 (isaralgagene civaparvovec) asset after beating bids from Astellas and TerSera Therapeutics. Sangamo will receive $111 million upfront from PTC, plus as much as $100 million in milestone payments tied to regulatory outcomes. The transaction consolidates the ST-920 franchise ahead of expected regulatory scrutiny. Sangamo had previously advanced a rolling biologics license application under an agreed accelerated approval pathway with the FDA, with Phase I/II STAAR data supporting the program’s potential efficacy and durability after enzyme replacement therapy withdrawal. Industry observers will be tracking how quickly PTC can transition the BLA-ready package, manage the program’s remaining regulatory steps, and position the therapy against existing Fabry treatments. Separately, the process underscores the volatility of gene-therapy portfolios when companies restructure under bankruptcy pressures.
-
Oncology trials: Taiho and Cullinan advance zipalertinib after early unblinding
Taiho Oncology and Cullinan Therapeutics said their Phase 3 trial of zipalertinib, a next-generation EGFR inhibitor, was stopped early at a planned interim analysis in front-line lung cancer with EGFR exon 20 insertion mutations. The partners reported that the oral drug plus chemotherapy met a pre-specified threshold for progression-free survival, triggering the unblinding. The update sets up a fresh regulatory timeline for the program. The FDA is already reviewing zipalertinib as a second-line treatment, with a decision expected by late February, while the new Phase 3 momentum could support an expanded label if the data hold across endpoints. The result intensifies competition in EGFR exon 20 insertion disease, where incumbents and other upcoming targeted options continue to battle for positioning in earlier lines. Taiho and Cullinan previously reported Phase 2 tumor shrinkage rates exceeding one-third of patients, supporting the rationale for moving quickly into Phase 3.
-
Oligonucleotide therapeutics: Silence upsizes public offering after Phase 2 ‘best-case’ signal
Silence Therapeutics priced an upsized public offering to raise about $175 million, targeting short interfering RNA (siRNA) programs including divesiran. The financing arrived after the company reported a “best-case” outcome in a Phase 2 study for divesiran in a rare leukemia indication. The share sale increases the originally proposed capital raise of roughly $150 million, with about 12.96 million American depositary shares priced at $13.50 each. Net proceeds are expected to support continued development across the company’s RNA pipeline and broader operational needs. For the biotech market, the deal underscores how quickly capital markets have responded to Phase 2 data—especially for platform-driven companies in the siRNA space where investors often focus on proof-of-concept signals and differentiation in dosing and durability.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.